▎WuXi AppTec Content Team Report

Atopic Dermatitis (AD) is a chronic, recurrent, inflammatory skin disease that severely impacts the physical and mental health of patients, bringing heavy pressure to families and society. Due to its chronic, recurrent, and highly heterogeneous nature, patients often find themselves trapped in a long-term cycle of "relapse-remission-relapse." Balancing rapid symptom control with long-term safety and stability throughout the entire course of the disease has become a challenge for clinicians.

In 2022, highly selective JAK1 inhibitors represented by Abrocitinib were launched in China. As a "necessary path" for new drug launches, Phase 3 clinical trials validated the drug's therapeutic effects and safety for target patients. Although these trials are considered the gold standard for evaluating drug efficacy and safety, the performance of innovative drugs in terms of efficacy and safety in China’s real-world settings has also drawn significant attention. Real-world studies collect and analyze data on drug usage in real medical environments, providing clinicians with more clinically relevant assessments of drug efficacy and safety. These studies offer scientific evidence to optimize clinical decision-making and advance personalized treatment practices, helping both doctors and patients make more informed treatment decisions and enhancing disease management and treatment confidence.

As an important achievement in the field of atopic dermatitis,Abrocitinib Updates Nine Studies at This Year's AAD Conference, Covering Multiple Dimensions Including Patient Itch, Skin Lesions, Quality of Life, and Drug SafetyAmong which, the interim results of the AHEAD study, a real-world investigation on abrocitinib, have been internationally released for the first time. The AHEAD study is a large-scale, multicenter, prospective, observational real-world study aimed at comprehensively understanding abrocitinib tablets.For Chinese patients with moderate to severe atopic dermatitisCharacteristics of the population, efficacy, and treatment patterns.

This interim result covers 314 patients from approximately 40 centers in China who received abrocitinib treatment from October 2023 to April 2024. The results show that the efficacy of abrocitinib in treating Chinese patients is consistent with the results of the global Phase 3 trial.In the second week, nearly 60% of patients achieved relief of itching symptoms, and nearly 30% of patients achieved PP-NRS0/1 response. Meanwhile, 61.6% of patients achieved a 75% improvement in skin lesions from baseline at week 12 of treatment. Nearly 40% of patients achieved success in the Investigator's Global Assessment (IGA).

The research findings of the JADE series on Abrocitinib will also be unveiled simultaneously, further strengthening the evidence of its efficacy benefits in improving itching, skin lesions, and quality of life for AD patients. It provides multidimensional supplementation of long-term safety evidence over the past five years, which helps enhance the precision of clinical decision-making and patient medication safety.

References:

[1] The world's largest real-world study of JAK1 inhibitors, AHEAD, and the JADE series data make their international debut. Retrieved Mar 8, 2025, from https://mp.weixin.qq.com/s/UMNxVYu2lbpWIpW5CB09_A